ApprovedFDA approval

Adquey (difamilast)

Acrotech Biopharma

Marketer take

A topical PDE4 inhibitor for mild-to-moderate atopic dermatitis, competing with Zoryve, Eucrisa and topical steroids for steroid-sparing positioning with dermatologists and pediatricians.

Sponsor company
Acrotech Biopharma
Indication
To treat mild to moderate atopic dermatitis
Therapeutic area
Dermatology
Event
FDA approval
Date
Feb 12, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move